Risperidone News and Research

RSS
Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

SureGene collaborates with Medco Health Solutions to conduct REST study

SureGene collaborates with Medco Health Solutions to conduct REST study

Johnson & Johnson second-quarter sales increase 0.6% to $15.3 billion

Johnson & Johnson second-quarter sales increase 0.6% to $15.3 billion

Psychotropic medications common among children with ASD: Research

Psychotropic medications common among children with ASD: Research

Johnson & Johnson' first-quarter 2010 sales increase 4.0% to $15.6 billion

Johnson & Johnson' first-quarter 2010 sales increase 4.0% to $15.6 billion

Obecure granted patent covering betahistine with olanzapine for mitigating antipsychotic drug associated weight gain

Obecure granted patent covering betahistine with olanzapine for mitigating antipsychotic drug associated weight gain

Obecure enters into licensing and clinical supply agreement with Grunenthal's subsidiary for XR betahistine

Obecure enters into licensing and clinical supply agreement with Grunenthal's subsidiary for XR betahistine

Autism Speaks: Ten most significant autism research achievements in 2009

Autism Speaks: Ten most significant autism research achievements in 2009

New Tel Aviv University study shows early intervention could prevent mind altering disorder

New Tel Aviv University study shows early intervention could prevent mind altering disorder

Atypical antipsychotic use for treating elderly patients with dementia decreases

Atypical antipsychotic use for treating elderly patients with dementia decreases

Majority of Medicaid patients on antipsychotic drugs do not undergo metabolic tests, says study

Majority of Medicaid patients on antipsychotic drugs do not undergo metabolic tests, says study

Behavior problems in children with autism can be reduced with a training program for parents

Behavior problems in children with autism can be reduced with a training program for parents

Pediatric and adolescent patients who receive antipsychotic medications experience weight gain

Pediatric and adolescent patients who receive antipsychotic medications experience weight gain

Johnson & Johnson announces financial results for the third quarter of 2009

Johnson & Johnson announces financial results for the third quarter of 2009

Add-on treatment may reduce treatment-associated weight gain caused by antipsychotic treatments

Add-on treatment may reduce treatment-associated weight gain caused by antipsychotic treatments

Paliperidone palmitate shows positive results for treatment of schizophrenia

Paliperidone palmitate shows positive results for treatment of schizophrenia

New plan to tackle off-label prescribing

New plan to tackle off-label prescribing

Mylan receives FDA approval for generic version of Risperdal

Mylan receives FDA approval for generic version of Risperdal

Study questions use of newer antipsychotic drugs in children

Study questions use of newer antipsychotic drugs in children

Newer atypical antipsychotic medications no better than older drug in treating child and adolescent schizophrenia

Newer atypical antipsychotic medications no better than older drug in treating child and adolescent schizophrenia